Dapagliflozin in STEMI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 256 participants.
Also called NCT06174753
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 256 participants
- Registry
-
NCT06174753
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT06174753. Randomized; triple masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin in STEMI
- Acronym
- DAPA STEMI
- Condition
- ST Elevation Myocardial Infarction
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Diagnostic test)
- CMR
- Lead sponsor
- Ottawa Heart Institute Research Corporation
Record details
- Record id
cardio:ct-nct06174753- Content hash
3f55ab840424d681a395fd272fa1d5d13619804c4386729685c0243a71a3bd7c